Article metrics

Download PDFPDF
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)

 

Online download statistics by month:

Online download statistics by month: October 2021 to June 2022

AbstractFullPdf
Oct 202126323219
Nov 20215861718
Dec 202119477
Jan 202225767
Feb 2022414137
Mar 2022490911
Apr 202230723
May 202228646
Jun 20226333022
Total5799120100